Monkeypox 2024 outbreak: Fifty essential questions and answers
Allergy · 2024-12 · 79 (12) · 3285-3309
DOI: 10.1111/all.16374 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Allergy, online erschienen am 04.11.2024. Verfasst von Beatriz Cabanillas und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy, Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. Hauptthemen laut MEDLINE: Disease Outbreaks, Mpox, Monkeypox, Monkeypox virus. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 204 Literaturangaben. Gefördert von: Instituto de Salud Carlos III (ISCIII) through project PI20/00351, co-funded by the European Union., Community of Madrid Talento Investigador program (Regional Ministry of Science, Universities, and Innovation, Madrid, Spain), under the projects 2023-5A/BIO-28…, Instituto de Salud Carlos III.
Abstract (Originalsprache)
As the world still vividly recalls the previous monkeypox (mpox) outbreak that impacted over 120 countries worldwide with more than 99,000 cases in 2022, we are now facing a second wave of infections from the monkeypox virus (MPXV), characterized by an exponential increase in cases. The current 2024 outbreak has already recorded more than 20,000 cases in Africa, marking a dramatic escalation compared to previous outbreaks. The predominance of the newly identified clade Ib variant, first detected in the Democratic Republic of the Congo (DRC) and now identified across multiple African nations and beyond, underscores its enhanced transmissibility and potential for international spread, evidenced by cases in Sweden and Thailand. The World Health Organization (WHO) declared on August 14, 2024, the current mpox outbreak a Public Health Emergency of International Concern (PHEIC), calling for heightened global public health measures. The ongoing pattern of unusual, frequent, and extensive outbreaks of mpox with potential global implications poses significant questions. This review addresses, in the format of 50 questions and answers, the 2024 mpox outbreak, detailing its characteristics, epidemiological data, and impact compared to previous outbreaks. It comprehensively explores critical questions related to MPXV virological characteristics, immunological response, clinical manifestations, epidemiology, diagnostics, and available treatments. The review also documents the significant and evolving challenges posed by the current mpox outbreak, highlighting its scale, spread, and public health response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Allergy, Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
- Department of Internal Medicine, University of Genova, Genova, Italy.
- Allergology and Clinical Immunology Unit, San Bartolomeo Hospital, Sarzana, Italy.
- IDESP and PREMEDICAL, University of Montpellier-INSERM, INRIA, Montpellier, France.
- Allergy Unit, Hospital Regional Universitario de Málaga, Allergy Research Group, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, ARADyAL, Malaga University, Málaga,…
- Department of Virology, Faculty of Veterinary Medicine, Kirikkale University, Kirikkale, Turkey.
ORCID-Profile: Beatriz Cabanillas, Giuseppe Murdaca, Amir Guemari, Maria Jose Torres, Ahmet Kursat Azkur, Emel Aksoy, Joana Vitte, Ruben Fernández-Santamaria, Riccardo Castagnoli, Esra Özek Yücel, Natalija Novak, Ioana Agache, Mubeccel Akdis, Cezmi A Akdis
Förderung
- Instituto de Salud Carlos III (ISCIII) through project PI20/00351, co-funded by the European Union.
- Community of Madrid Talento Investigador program (Regional Ministry of Science, Universities, and Innovation, Madrid, Spain), under the projects 2023-5A/BIO-28…
- Instituto de Salud Carlos III
Zitieren
APA
Cabanillas, B., Murdaca, G., Guemari, A., Torres, M. J., Azkur, A. K., Aksoy, E., Vitte, J., Fernández-Santamaria, R., Karavelia, A., Castagnoli, R., Valdelvira, R., Orsi, A., Ogliastro, M., Massaro, E., Yücel, E. Ö., Novak, N., Agache, I., Akdis, M., & Akdis, C. A. (2024). Monkeypox 2024 outbreak: Fifty essential questions and answers. Allergy, 79(12), 3285-3309. https://doi.org/10.1111/all.16374
Vancouver
Cabanillas B, Murdaca G, Guemari A, Torres MJ, Azkur AK, Aksoy E, et al. Monkeypox 2024 outbreak: Fifty essential questions and answers. Allergy. 2024;79(12):3285-3309. doi:10.1111/all.16374
BibTeX
@article{Cabanillas2024,
author = {Cabanillas, Beatriz and Murdaca, Giuseppe and Guemari, Amir and Torres, Maria Jose and Azkur, Ahmet Kursat and Aksoy, Emel and Vitte, Joana and Fernández-Santamaria, Ruben and Karavelia, Aspasia and Castagnoli, Riccardo and Valdelvira, Rafael and Orsi, Andrea and Ogliastro, Matilde and Massaro, Elvira and Yücel, Esra Özek and Novak, Natalija and Agache, Ioana and Akdis, Mubeccel and Akdis, Cezmi A},
title = {Monkeypox 2024 outbreak: Fifty essential questions and answers},
journal = {Allergy},
year = {2024},
volume = {79},
number = {12},
pages = {3285--3309},
doi = {10.1111/all.16374}
}
EUVIMED